Premature Cancer-Related Morbidity and Mortality in Israel: Years Lived With Disability and Years of Life Lost Productivity Costs
Author(s)
Shira Yaari, PhD1, Sharon Pelles Avraham, PhD2, Guy Tavori, M Sc3, Galit Gilad, M Sc4, Keren Dodick, M Sc1, Anne Meiwald, M Sc5, Aimee Fox, PhD6, Peter Toth, M Sc6, Chamath Perera, M Sc6, Bernadette Poellinger, PhD7.
1MSD Merck Sharp & Dohme, Tel Aviv, Israel, 2Unit- Barzilai Medical center, Tel Aviv, Israel, 3All Can, Tel Aviv, Israel, 4MSD, Hod Hasharon, Israel, 5Adelphi Values, Bollington, United Kingdom, 6Adelphi Values PROVE, Bollington, United Kingdom, 7Director Oncology Outcomes Research, MSD, München, Germany.
1MSD Merck Sharp & Dohme, Tel Aviv, Israel, 2Unit- Barzilai Medical center, Tel Aviv, Israel, 3All Can, Tel Aviv, Israel, 4MSD, Hod Hasharon, Israel, 5Adelphi Values, Bollington, United Kingdom, 6Adelphi Values PROVE, Bollington, United Kingdom, 7Director Oncology Outcomes Research, MSD, München, Germany.
OBJECTIVES: This study aims to provide a perspective on the cancer morbidity and mortality burden and productive life lost in Israel in 2022.
METHODS: Institute for Health Metrics and Evaluation (IHME) data was used to estimate for age, sex and cancer-specific deaths. Years lived with disability (YLD) were used to estimate value of years lived with disability (VYLD) for morbidity. Years of life lost (YLL) were used to estimate years of productive life lost (i.e. years lost before retirement age [60 years]) and present value of future lost productivity (PVFLP) for mortality. Labor force participation and unemployment rate were sourced from the World Bank and national government sources.
RESULTS: In Israel, cancer malignancies resulted in overall 15,028 YLD in 2022, with pancreatic cancer accounting for 244, lung for 670, colorectum for 2,142 and breast for 3,563 YLD, respectively. Annual VYLD was estimated to be $189,712,444 for all cancer types, with lung accounting for $8,587,373, colorectum for $22,860,888, breast for $41,124,524 and pancreatic cancer for $2,476,305 respectively. 14,657 patients died of cancer in Israel in 2022. Lung, colorectum, breast and pancreatic cancer were malignancies with high mortality with an estimated number of 2,601; 1,956; 1,432 and 1,335 deaths, respectively. The total deaths resulted in overall 296,240 YLL, with lung accounting for 54,392, colorectum for 34,807, breast for 31,213 and pancreatic cancer for 26,216 YLL in 2022. Annual PVFLP was estimated to be $926,021,209 for all cancer types, with lung accounting for $165,058,222, colorectum for $89,083,376, breast for $90,294,429 and pancreatic cancer for $68,856,437 respectively.
CONCLUSIONS: The societal burden in Israel with lung, colorectum, breast and pancreatic cancers is significant due to premature cancer morbidity and mortality. Investing in early diagnosis, symptom awareness, and accessible treatments is crucial. Cancer survivors need support to resume daily routines and maintain productivity.
METHODS: Institute for Health Metrics and Evaluation (IHME) data was used to estimate for age, sex and cancer-specific deaths. Years lived with disability (YLD) were used to estimate value of years lived with disability (VYLD) for morbidity. Years of life lost (YLL) were used to estimate years of productive life lost (i.e. years lost before retirement age [60 years]) and present value of future lost productivity (PVFLP) for mortality. Labor force participation and unemployment rate were sourced from the World Bank and national government sources.
RESULTS: In Israel, cancer malignancies resulted in overall 15,028 YLD in 2022, with pancreatic cancer accounting for 244, lung for 670, colorectum for 2,142 and breast for 3,563 YLD, respectively. Annual VYLD was estimated to be $189,712,444 for all cancer types, with lung accounting for $8,587,373, colorectum for $22,860,888, breast for $41,124,524 and pancreatic cancer for $2,476,305 respectively. 14,657 patients died of cancer in Israel in 2022. Lung, colorectum, breast and pancreatic cancer were malignancies with high mortality with an estimated number of 2,601; 1,956; 1,432 and 1,335 deaths, respectively. The total deaths resulted in overall 296,240 YLL, with lung accounting for 54,392, colorectum for 34,807, breast for 31,213 and pancreatic cancer for 26,216 YLL in 2022. Annual PVFLP was estimated to be $926,021,209 for all cancer types, with lung accounting for $165,058,222, colorectum for $89,083,376, breast for $90,294,429 and pancreatic cancer for $68,856,437 respectively.
CONCLUSIONS: The societal burden in Israel with lung, colorectum, breast and pancreatic cancers is significant due to premature cancer morbidity and mortality. Investing in early diagnosis, symptom awareness, and accessible treatments is crucial. Cancer survivors need support to resume daily routines and maintain productivity.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EPH186
Topic
Economic Evaluation, Epidemiology & Public Health, Health Policy & Regulatory
Disease
Oncology